The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Jazz Pharmaceuticals

  • JAZZ
  • NASDAQ
  • Consumer Products
  • Latest 136.155
  • Currency US$
  • Change 0.055
  • Percent Change 0.04 %
  • Volume 1,066,653
  • Thu Apr 17, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 137.86
  • Previous Close 136.155
  • High 140.44
  • Low 134.04
  • Bidx0 0.0000
  • Askx0 0.0000
  • 52-week High02/25 176.601
  • 52-week Low05/08 50.76
  • Beta 0.488
  • Market Cap 7,868.40M
  • EPS 3.51
  • P/E 38.791
  • Forward P/E 14.20
  • PEG 0.87
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $872,420,000
  • Earnings $216,310,000
  • Return on Equity 17.04%

Cash Flow

  • Cash Flow --
  • Cash $636,500,000
  • Current Ratio 4.24

12 months ended Dec 31, 2013.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $2,238,220,000
  • Liabilities $942,680,000
  • Liabilities-to-Equity Ratio 0.73

Price Ratios

  • Price to Sales 9.02
  • Price to Book 6.07
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Feb 25 $1.65 May 6 n/a
Surprises Feb 25 -7.88% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Apr 20, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and acquisition/in-licensing activities and to utilize our specialty sales force to promote products in our target markets. They apply novel formulations and drug delivery technologies to known drug compounds, and compounds with the same mechanism of action or similar chemical structure as marketed products, to improve patient care by improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies. Based in Palo Alto, California, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals.

Related Securities
Symbol Type Latest % Chg

Officers

  • Bruce C. Cozadd Chairman; C.E.O. and Director
  • Kathryn E. Falberg Executive V.P. and C.F.O.
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

4TH FLOOR CONNAUGHT HOUSE ONE
DUBLIN, L2
4

Phone: (353)-1634-7800

investorinfo@jazzpharma.com
www.jazzpharma.com

Ideas & Discussion

Live Discussion of JAZZ on StockTwits